

10/019355

531 Rec'd PCT.

19 OCT 2001

a

**"EXPRESS MAIL CERTIFICATE"****"EXPRESS MAIL" MAILING LABEL NUMBER EV000521179US****DATE OF DEPOSIT 19 OCTOBER 2001**

Attorney Docket No. P32286

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/GB00/01521	19 April 2000	20 April 1999

TITLE OF INVENTION  
NOVEL PHARMACEUTICAL

APPLICANT(S) FOR DO/US

Paul David James BLACKLER, Robert Gordon GILES and Michael John SASSE

**PRELIMINARY AMENDMENT**

Preliminary to the examination of this application, Applicants respectfully request amendment of the above-identified application as follows:

**In the Specification:**

Kindly add the Abstract enclosed herewith on a separate sheet, at the end.

**In the Claims:**

Please cancel claims 9-11.

Please amend claims 1, 3-6, and 12 as follows:

1. (Amended) 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride dihydrate comprising:

(ii) provides an infrared spectrum containing peaks at 3392, 2739, 1751, 1325 and 713 cm<sup>-1</sup>; and/or

(ii) provides an X-ray powder diffraction (XRPD) pattern containing peaks at 9.1, 12.0, 15.7, 16.3 and 19.8 °2θ.

3. (Amended) A hydrate according to claim 1, which provides an X-ray powder diffraction (XRPD) pattern substantially in accordance with Figure II.

4. (Amended) A hydrate according to claim 1, in isolated form.

5. (Amended) A hydrate according to claim 1, in pure form.

6. (Amended) A hydrate according to claim 1, in crystalline form.